

NHS Greater Glasgow and Clyde: New Medicines Decisions

In Scotland, a newly licensed medicine is routinely available in a health board only after it has been:

- accepted for use in NHSScotland by the Scottish Medicines Consortium (SMC), and
- accepted for use by the health board's Area Drug and Therapeutics Committee (ADTC).

All medicines accepted by SMC are available in Scotland, but may not be considered 'routinely available' within NHS Greater Glasgow and Clyde (NHSGG&C) because of available services and preferences.

'Routinely available' means that a medicine can be prescribed by the appropriately qualified person within a health board.

Each health board has an ADTC. The Greater Glasgow and Clyde ADTC is responsible for advising the NHSGG&C health board on all aspects of the use of medicines.

Medicines routinely available within NHSGG&C are usually included in the GGC Formulary. The Formulary is a list of medicines for use in the health board that has been agreed by ADTC in consultation with healthcare professionals to prescribe for common medical conditions. The GGC Formulary can help improve safety as prescribers are likely to become more familiar with the medicines included and are consistent across the health board.

How does NHSGG&C decide which new medicines to make routinely available for patients?

The ADTC in NHSGG&C will consider national and local guidance before deciding whether to make a new medicine routinely available.

What national guidance does the ADTC consider?

- SMC advice: The SMC considers newly licensed medicines and advises health boards in Scotland whether they should be available. When SMC considers a new medicine for the NHS in Scotland
 - how well the medicine works,
 - which patients might benefit from it,
 - whether it is as good or better than medicines the NHS already uses to treat the medical condition, and
 - whether it is good value for money.
- In the table below, national guidance usually refers to SMC advice. Links to SMC advice for individual medicines are also included in the table.
- In some cases, other agencies may also provide guidance on how medicines should be used. For example, Healthcare Improvement Scotland issues alerts to advise if National Institute for Health and Care Excellence (NICE) Appraisals (NICE MTAs) are applicable in Scotland.

What local guidance does the ADTC consider?

- Advice from local clinical experts who would be expected to prescribe a particular medicine, where that service is available in NHSGG&C.

Why is a particular medicine not routinely available in NHSGG&C?

- This is usually because the medicine is not recommended for use in NHSScotland by the SMC.
- The medicine may not be routinely available in a health board, particularly in smaller health boards, because there is not a suitable specialist who may use the medicine.
- There may also be differences in which medicines are preferred in health boards. Sometimes SMC accepts more than one medicine for treating a specific medical condition. Clinical experts in each health board advise the ADTC. Sometimes it is agreed that established medicines are a better choice than new medicines.

Medicine	Condition being treated	NHSGGC Decision	Date of decision
----------	-------------------------	-----------------	------------------

amivantamab	In combination with lazertinib for the first line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 19 deletions or Exon 21 L858R substitution mutations.	Routinely available in line with local or regional guidance	17/08/2026
Rybrevant®			
SMC2834			
Arsenic trioxide, all-trans retinoic acid (ATRA [tretinoin])	Treatment of high-risk acute promyelocytic leukaemia	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by:	17/08/2026
NCMAG127		19/10/2026	
avapritinib	Monotherapy for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated haematological neoplasm (SM-AHN), or mast cell leukaemia (MCL).	Not routinely available as not recommended for use in NHSScotland	17/08/2026
Ayvakyt®			
SMC2849			
axicabtagene ciloleucel	Treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by:	17/08/2026
Yescarta®		07/12/2026	
SMC2695			

Medicine	Condition being treated	NHSGGC Decision	Date of decision
belantamab mafodotin Blenrep SMC2727	in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 07/12/2026	17/08/2026
benralizumab Fasenra® SMC2870	Add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA).	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 07/12/2026	17/08/2026
cabozantinib Cabozantinib Ipsen® SMC2967	Treatment of adult patients with unresectable or metastatic, well-differentiated extra-pancreatic (epNET) and pancreatic (pNET) neuroendocrine tumours who have progressed following at least one prior systemic therapy other than somatostatin analogues.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 19/10/2026	17/08/2026
cabozantinib SMC2754	Monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 07/12/2026	17/08/2026

Medicine	Condition being treated	NHSGGC Decision	Date of decision
capsaicin Qutenza® SMC2861	0 Treatment of peripheral neuropathic pain in adults either alone or in combination with other medicinal products for the treatment of pain	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 07/12/2026	17/08/2026
Dermatophagoides pteronyssinus, Dermatophagoides farinae Acarizax® SMC2885	0 Treatment of adult patients (18-65 years) diagnosed by clinical history and a positive test of house dust mite sensitisation (skin prick test and/or specific immunoglobulin E (IgE) with at least one of the following conditions: • persistent moderate to severe house dust mite allergic rhinitis despite use of symptom-relieving medication • house dust mite allergic asthma not well controlled by inhaled corticosteroids and associated with mild to severe house dust mite allergic rhinitis. Patients' asthma status should be carefully evaluated before the initiation of treatment.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 19/10/2026	17/08/2026
dostarlimab Jemperli® SMC2953	0 In combination with platinum-containing chemotherapy for the treatment of adult patients with primary advanced or recurrent endometrial cancer and who are candidates for systemic therapy.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 19/10/2026	17/08/2026

Medicine	Condition being treated	NHSGGC Decision	Date of decision
dupilumab Dupixent® SMC2851	0 As an add-on therapy with intranasal corticosteroids for the treatment of adults with severe chronic rhinosinusitis with nasal polyps for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control.	Routinely available in line with national guidance	17/08/2026
durvalumab Imfinzi® SMC2818	0 Monotherapy for the treatment of adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following platinum-based chemoradiation therapy.	Routinely available in line with local or regional guidance	17/08/2026
durvalumab Imfinzi® SMC2880	0 In combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by durvalumab as monotherapy adjuvant treatment after radical cystectomy, for the treatment of adults with resectable muscle invasive bladder cancer (MIBC).	Routinely available in line with local or regional guidance	17/08/2026
efgartigimod alfa SMC2964	0 Monotherapy for the treatment of adult patients with progressive or relapsing active chronic inflammatory demyelinating polyneuropathy (CIDP) after prior treatment with corticosteroids or immunoglobulins	Not routinely available as not recommended for use in NHSScotland	17/08/2026

Medicine	Condition being treated	NHSGGC Decision	Date of decision
elinzanetant Lynkuet® SMC2965	Treatment of moderate to severe vasomotor 0 symptoms (VMS) associated with menopause.	Not routinely available as not recommended for use in NHSScotland	17/08/2026
enfortumab vedotin Padcev® SMC2842	In combination with pembrolizumab, for the first- 0 line treatment of adult patients with unresectable or metastatic urothelial cancer who are eligible for platinum-containing chemotherapy.	Routinely available in line with local or regional guidance	17/08/2026
exagamglogene autotemcel Casgevy® SMC2852	Treatment of sickle cell disease in patients 12 0 years of age and older with recurrent vaso- occlusive crises who have the β S/ β S, β S/ β + or β S/ β 0 genotype, for whom haematopoietic stem cell transplantation is appropriate and a human leukocyte antigen matched related haematopoietic stem cell donor is not available.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 19/10/2026	17/08/2026
fezolinetant Veoza® SMC2898	Treatment of moderate to severe vasomotor 0 symptoms (VMS) associated with menopause.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 07/12/2026	17/08/2026

Medicine	Condition being treated	NHSGGC Decision	Date of decision
glofitamab Columvi® SMC2846	0 In combination with gemcitabine and oxaliplatin for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS) who are ineligible for autologous stem cell transplant (ASCT).	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 19/10/2026	17/08/2026
isatuximab Sarclisa® SMC2804	0 In combination with bortezomib, lenalidomide, and dexamethasone, for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.	Routinely available in line with local or regional guidance	17/08/2026
levodopa, carbidopa, entacapone Lecigon® SMC2876	0 Treatment of advanced Parkinson's disease with severe motor fluctuations and hyperkinesia or dyskinesia when available oral combinations of Parkinson medicinal products have not given satisfactory results.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 07/12/2026	17/08/2026
lutetium, vipivotide tetraxetan Pluvicto® SMC2966	0 Treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have progressed on or after treatment with androgen receptor pathway inhibitor (ARPI) therapy and are considered appropriate to delay taxane-based chemotherapy	Not routinely available as not recommended for use in NHSScotland	17/08/2026

Medicine	Condition being treated	NHSGGC Decision	Date of decision
nemolizumab Nemluvio® SMC2833	0 Treatment of moderate-to-severe atopic dermatitis in combination with topical corticosteroids and/or calcineurin inhibitors in adults and adolescents 12 years and older with a body weight of at least 30 kg, who are candidates for systemic therapy.	Routinely available in line with national guidance	17/08/2026
Pazopanib NCMAG128	0 Soft tissue sarcoma	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 19/10/2026	17/08/2026
ribociclib Kisqali® SMC2803	0 In combination with an aromatase inhibitor for the adjuvant treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer at high risk of recurrence. In pre- or perimenopausal women, or in men, the aromatase inhibitor should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 07/12/2026	17/08/2026
Semaglutide Wegovy SMC2497	0 An adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of • ≥30kg/m2 (obesity), or • ≥27kg/m2 to <30kg/m2 (overweight) in the presence of at least one weight-related comorbidity.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 19/10/2026	17/08/2026

Medicine	Condition being treated	NHSGGC Decision	Date of decision
semaglutide Wegovy® SMC2872	0 As an adjunct to a reduced-calorie diet and increased physical activity to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight (BMI ≥27 kg/m2)	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 07/12/2026	17/08/2026
sodium zirconium cyclosilicate Lokelma® SMC2884	0 Treatment of hyperkalaemia in adult patients	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 19/10/2026	17/08/2026
sotatercept Winrevair® SMC2923	0 In combination with other pulmonary arterial hypertension (PAH) therapies, for the treatment of PAH in adult patients with WHO Functional Class (FC) II to III, to improve exercise capacity.	Routinely available in line with national guidance	17/08/2026
talquetamab Talvey® SMC2863	0 Monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy	Routinely available in line with local or regional guidance	17/08/2026

Medicine	Condition being treated	NHSGGC Decision	Date of decision
tebentafusp Kimmtrak® SMC2910	0 Monotherapy for the treatment of human leukocyte antigen (HLA)-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 19/10/2026	17/08/2026
tirzepatide Mounjaro® SMC2653	0 For weight management, including weight loss and weight maintenance, as an adjunct to a reduced-calorie diet and increased physical activity in adults with an initial Body Mass Index (BMI) of ≥30 kg/m2 (obesity) or ≥27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus).	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 19/10/2026	17/08/2026
upadacitinib Rinvoq® SMC2879	0 Treatment of giant cell arteritis in adult patients	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 07/12/2026	17/08/2026
vanzacaftor, tezacaftor, deutivacaftor Alyftrek® SMC2800	0 Treatment of cystic fibrosis (CF) in people aged 6 years and older who have at least one F508del mutation or another responsive mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene	Routinely available in line with national guidance	17/08/2026

Medicine	Condition being treated	NHSGGC Decision	Date of decision
zilucoplan Zilbrysq® SMC2955	0 As an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 07/12/2026	17/08/2026
zolbetuximab Vyloy® SMC2839	0 In combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adult patients with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastro-oesophageal junction (GEJ) adenocarcinoma whose tumours are Claudin (CLDN) 18.2 positive.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 07/12/2026	17/08/2026